EUVIMEDOpdag EUVIMED
Open access

Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance

Marianne E M Yee iD, Patricia E Zerra, James W McCoy, Mischa L Covington iD, Sean R Stowell iD, Clinton H Joiner, Christopher M Lough, Bhaveshkumar B Delvadia, Cassandra D Josephson, John D Roback, Ross M Fasano iD

Transfusion · 2024

DOI: 10.1111/trf.17800 ↗

At a glance

Journal article in Transfusion, 2024. Written by Marianne E M Yee and 10 co-authors. Institution: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Major MEDLINE topics: Anemia, Sickle Cell, Erythrocytes, Biotin, Autoantibodies. Cited 7 times so far (Crossref); 34 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Red blood cell (RBC) antibodies are common in multiply transfused patients with sickle cell disease (SCD). Unlike RBC alloantibodies, the potential of autoantibodies to cause post‐transfusion hemolysis may be uncertain. Biotin‐labeling provides a direct measurement of red cell survival (RCS) over time, thus can be used to assess the clinical significance of RBC antibodies. Antibodies to biotinylated RBC (B‐RBC) occasionally are detected after exposure, which may impact B‐RBC survival in subsequent RCS studies. Study Design and Methods Pediatric patients with SCD receiving monthly chronic transfusions underwent RCS studies, receiving aliquots of allogeneic RBC labeled at distinct densities of biotin (2–18 μg/mL). B‐RBC survival was followed for 4 months post‐transfusion, and B‐RBC antibody screening for 6 months. Patients with warm autoantibodies (WAA) or B‐RBC antibodies are reported here.

Results

RBC antibodies were detected during RCS in four patients: one with WAA, one with WAA followed by B‐RBC‐specific antibodies, and two with transient B‐RBC antibodies within the first 5 weeks of exposure. B‐RBC half‐lives (T 50 ) ranged 37.6–61.7 days (mean 47.8 days). There was no evidence of increased hemolysis or accelerated B‐RBC clearance in the presence of WAA or B‐RBC antibodies.

Discussion

Biotinylation of allogenic RBC can be used to assess the possible effects of RBC antibodies on transfusion survival in individual cases, particularly when it is uncertain if the detected antibodies may result in hemolysis. In the cases presented here, neither WAA nor B‐RBC antibodies were associated with significant shortening of B‐RBC survival in individuals with SCD.

Subjects

MeSH terms (MEDLINE)

Anemia, Sickle CellErythrocytesBiotinAutoantibodiesErythrocyte TransfusionHumansChildMaleAdolescentFemaleCell SurvivalBiotinylationChild, PreschoolIsoantibodiesHemolysis

Author keywords

RBC autoantibodiesbiotinred cell survivalsickle cell disease

Substances

BiotinAutoantibodiesIsoantibodies

Authors and institutions

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Medical Services, Lifesouth Community Blood Centers, Gainesville, Florida, USA.
  • Transfusion Services, Northside Hospital, Atlanta, Georgia, USA.

ORCID profiles: Marianne E M Yee, Mischa L Covington, Sean R Stowell, Ross M Fasano

Funding

  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Yee, M. E. M., Zerra, P. E., McCoy, J. W., Covington, M. L., Stowell, S. R., Joiner, C. H., Lough, C. M., Delvadia, B. B., Josephson, C. D., Roback, J. D., & Fasano, R. M. (2024). Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance. Transfusion. https://doi.org/10.1111/trf.17800

Vancouver

Yee MEM, Zerra PE, McCoy JW, Covington ML, Stowell SR, Joiner CH, et al. Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance. Transfusion. 2024. doi:10.1111/trf.17800

BibTeX
@article{Yee2024,
  author = {Yee, Marianne E M and Zerra, Patricia E and McCoy, James W and Covington, Mischa L and Stowell, Sean R and Joiner, Clinton H and Lough, Christopher M and Delvadia, Bhaveshkumar B and Josephson, Cassandra D and Roback, John D and Fasano, Ross M},
  title = {Post‐transfusion biotin‐labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17800}
}
Start for free →